Effect of Erythropoietin on Hepatic Cytochrome P450 Expression and Function in an Adenine-fed Rat Model of Chronic Kidney Disease

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2014 Sep 16

PMID 25219905

Citations 7

Authors

D A Feere

T J Velenosi

B L Urquhart

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Erythropoietin (EPO) is used to treat anaemia associated with chronic kidney disease (CKD). Hypoxia is associated with anaemia and is known to cause a decrease in cytochrome P450 (P450) expression. As EPO production is regulated by hypoxia, we investigated the role of EPO on P450 expression and function.

Experimental Approach: Male Wistar rats were subjected to a 0.7% adenine diet for 4 weeks to induce CKD. The diet continued for an additional 2 weeks while rats received EPO by i.p. injection every other day. Following euthanasia, hepatic P450 mRNA and protein expression were determined. Hepatic enzyme activity of selected P450s was determined and chromatin immunoprecipitation was used to characterize binding of nuclear receptors involved in the transcriptional regulation of CYP2C and CYP3A.

Key Results: EPO administration decreased hepatic mRNA and protein expression of CYP3A2 (P < 0.05), but not CYP2C11. Similarly, EPO administration decreased CYP3A2 protein expression by 81% (P < 0.001). A 32% decrease (P < 0.05) in hepatic CYP3A enzymatic activity (Vmax ) was observed for the formation of 6βOH-testosterone in the EPO-treated group. Decreases in RNA pol II recruitment (P < 0.01), hepatocyte nuclear factor 4α binding (P < 0.05) and pregnane X receptor binding (P < 0.01) to the promoter region of CYP3A were also observed in EPO-treated rats.

Conclusions And Implications: Our data show that EPO decreases the expression and function of CYP3A, but not CYP2C in rat liver.

Citing Articles

Autophagy-modulating biomaterials: multifunctional weapons to promote tissue regeneration.

Wu Y, Li L, Ning Z, Li C, Yin Y, Chen K Cell Commun Signal. 2024; 22(1):124.

PMID: 38360732 PMC: 10868121. DOI: 10.1186/s12964-023-01346-3.

Paradoxical reduction of plasma lipids and atherosclerosis in mice with adenine-induced chronic kidney disease and hypercholesterolemia.

Padalkar M, Tsivitis A, Gelfman Y, Kasiyanyk M, Kaungumpillil N, Ma D Front Cardiovasc Med. 2023; 10:1088015.

PMID: 36844738 PMC: 9947538. DOI: 10.3389/fcvm.2023.1088015.

Erythropoietin attenuates locomotor and cognitive impairments in male rats subjected to physical and psychological stress.

Fathi M, Tahamtan M, Kohlmeier K, Shabani M IBRO Neurosci Rep. 2022; 12:303-308.

PMID: 35519433 PMC: 9062441. DOI: 10.1016/j.ibneur.2022.04.006.

Folic acid-induced animal model of kidney disease.

Yan L Animal Model Exp Med. 2022; 4(4):329-342.

PMID: 34977484 PMC: 8690981. DOI: 10.1002/ame2.12194.

The effect of chronic kidney disease on CYP2B expression and activity in male Wistar rats.

Kucey A, Velenosi T, Tonial N, Tieu A, RaoPeters A, Urquhart B Pharmacol Res Perspect. 2019; 7(3):e00475.

PMID: 31049204 PMC: 6484215. DOI: 10.1002/prp2.475.

References

Wienkers L, Heath T . Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005; 4(10):825-33. DOI: 10.1038/nrd1851. View

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

Manley H, Garvin C, Drayer D, Reid G, Bender W, Neufeld T . Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004; 19(7):1842-8. DOI: 10.1093/ndt/gfh280. View

Wrighton S, Schuetz E, Watkins P, Maurel P, Barwick J, Bailey B . Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Mol Pharmacol. 1985; 28(3):312-21. View

Chovan J, Ring S, Yu E, Baldino J . Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica. 2007; 37(5):459-73. DOI: 10.1080/00498250701245250. View

McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C . Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol. 2010; 160(7):1573-6. PMC: 2936829. DOI: 10.1111/j.1476-5381.2010.00873.x. View

Lichti-Kaiser K, Brobst D, Xu C, Staudinger J . A systematic analysis of predicted phosphorylation sites within the human pregnane X receptor protein. J Pharmacol Exp Ther. 2009; 331(1):65-76. PMC: 2766221. DOI: 10.1124/jpet.109.157180. View

Diwan V, Mistry A, Gobe G, Brown L . Adenine-induced chronic kidney and cardiovascular damage in rats. J Pharmacol Toxicol Methods. 2013; 68(2):197-207. DOI: 10.1016/j.vascn.2013.05.006. View

Lacombe C, Da Silva J, Bruneval P, Fournier J, Wendling F, Casadevall N . Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988; 81(2):620-3. PMC: 329613. DOI: 10.1172/JCI113363. View

10.

Legendre C, Hori T, Loyer P, Aninat C, Ishida S, Glaise D . Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur J Cancer. 2009; 45(16):2882-92. DOI: 10.1016/j.ejca.2009.07.010. View

11.

Fried W . The liver as a source of extrarenal erythropoietin production. Blood. 1972; 40(5):671-7. View

12.

Srai S, Chung B, Marks J, Pourvali K, Solanky N, Rapisarda C . Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int. 2010; 78(7):660-7. DOI: 10.1038/ki.2010.217. View

13.

Wang G, Semenza G . General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993; 90(9):4304-8. PMC: 46495. DOI: 10.1073/pnas.90.9.4304. View

14.

Nolin T, Frye R, Le P, Sadr H, Naud J, Leblond F . ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009; 20(10):2269-76. PMC: 2754095. DOI: 10.1681/ASN.2009010082. View

15.

Ibeanu G, Goldstein J . Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry. 1995; 34(25):8028-36. DOI: 10.1021/bi00025a008. View

16.

Lu K, Ching L, Su K, Yu Y, Kou Y, Hsiao S . Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation. 2010; 121(16):1828-37. DOI: 10.1161/CIRCULATIONAHA.109.876839. View

17.

John S, Vinkemeier U, Soldaini E, Darnell Jr J, Leonard W . The significance of tetramerization in promoter recruitment by Stat5. Mol Cell Biol. 1999; 19(3):1910-8. PMC: 83984. DOI: 10.1128/MCB.19.3.1910. View

18.

Zanger U, Schwab M . Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41. DOI: 10.1016/j.pharmthera.2012.12.007. View

19.

Fradette C, Bleau A, Pichette V, Chauret N, du Souich P . Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators. Br J Pharmacol. 2002; 137(6):881-91. PMC: 1573556. DOI: 10.1038/sj.bjp.0704933. View

20.

Parganas E, Wang D, Stravopodis D, Topham D, Marine J, Teglund S . Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998; 93(3):385-95. DOI: 10.1016/s0092-8674(00)81167-8. View